Viscous formulations and their use in needle-free injection
Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which can have 0.5 ml or more administered by a needle-free injector in about 0.1 second ±0.02 seconds.
1. A needle free injector device, comprising:
a container;
a liquid formulation comprised of a pharmaceutically acceptable carrier and pharmaceutically active drug in the container, the formulation having a viscosity of 5 cS or more at 20° C.; and
a nozzle leading from the container, the nozzle comprising a channel and an exit opening;
wherein the nozzle has a ratio of channel length to exit opening diameter of less than 7.
2. The injector of claim 1 , wherein the viscosity of the liquid is more than 10 cS at 20° C.
3. The injector of claim 2 , wherein the formulation is a viscous controlled release formulation.
4. The injector of claim 2 , wherein the pharmaceutically active drug comprises a protein.
5. The injector of claim 4 , wherein the protein is selected from the group consisting of oxytocin, vasopressin,adrenocorticotropic hormone, epidermal growth factor, platelet-derived growth factor (PDGF), prolactin, luliberin, luteinizing hormone releasing hormone (LHRH), LHRH agonists, LHRH antagonists, growth hormone (human, porcine, bovine, etc.), growth hormone releasing factor, insulin, erythropoietin, somatostatin, glucagon, interleukin-2 (IL-2), interferon-.alpha.,.beta., or . gamma. , gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), heparinase, bone morphogenic protein (BMP), hANP, glucagon-like peptide (GLP-1), interleukin-11 (IL-11), renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidine, gramicidins, cyclosporins and synthetic analogues, modifications and pharmacologically active fragments thereof, enzymes, cytokines, antibodies, vaccines and polymers, which may be copolymers or conjugates comprised of poly(ortho esters).
6. The injector of claim 1 , wherein the viscosity of the liquid is 20 cS or more at 20° C. and the ratio of channel length to exit opening diameter is less than 5.
7. The injector of claim 1 , wherein the viscosity of the formulation is 100 cS or more at 20° C.
8. The injector of claim 1 , wherein the ratio of channel length to exit opening diameter is 1.7 ±20%.
9. The injector of claim 1 , wherein the viscosity of the formulation is 1000 cS or more at 20° C.
10. The needle free injector of claim 1 , wherein the drug is a psychiatric drug.
11. The injector of claim 10 , wherein the psychiatric drug is selected from the group consisting of chlorpromazine, fluphenazine, mesoridazine, perphenazine, prochlorperazine, promazine, thioridazine/sulforidazine, trifluoperazine, indoles, butyrophenones, thioxanthenes, diphenylbutylpiperidines, loxapine, butyrophenones, indoles, benzamides, diazepines, oxazepines, thiazepines, aripiprazole, risperidone, paliperidone, zotepine, iloperidone, pharmaceutically acceptable salt and ester forms thereof, and combinations of two or more of these compounds.
12. The injector of claim 10 , wherein the psychiatric drug is selected from the group consisting of molindone, azaperone, benperidol, droperidol, haloperidol, flupentixol, chlorprothixene, thiothixene, zuclopenthixol, fluspirilene, penfluridol, pimozide, loxapine, melperone, sertindole, ziprasidone, sulpiride, remoxipride, amisulpride, clozapine, olanzapine, quetiapine, and pharmaceutically acceptable salts and ester forms, and combinations thereof.
13. The injector of claim 10 , wherein the psychiatric drug comprises risperidone.
14. The injector of claim 13 , wherein the formulation comprises sucrose acetate isobutyrate.
15. The injector of claim 1 , wherein the pharmaceutically active drug comprises a protein.
16. The injector of claim 15 , wherein the protein is selected from the group consisting of oxytocin, vasopressin,adrenocorticotropic hormone, epidermal growth factor, platelet-derived growth factor (PDGF), prolactin, luliberin, luteinizing hormone releasing hormone (LHRH), LHRH agonists, LHRH antagonists, growth hormone (human, porcine, bovine, etc.), growth hormone releasing factor, insulin, erythropoietin, somatostatin, glucagon, interleukin-2 (IL-2), interferon-.alpha.,.beta., or . gamma. , gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), heparinase, bone morphogenic protein (BMP), hANP, glucagon-like peptide (GLP-1), interleukin-11 (IL-11), renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidine, gramicidins, cyclosporins and synthetic analogues, modifications and pharmacologically active fragments thereof, enzymes, cytokines, antibodies, vaccines and polymers, which may be copolymers or conjugates comprised of poly(ortho esters).
17. A needle free injector device, comprising:
a container;
a liquid formulation comprised of a pharmaceutically acceptable carrier and pharmaceutically active drug in the container, the formulation having a viscosity of 5 cS or more at 20° C.;
a nozzle leading from the container, the nozzle comprising a channel and an exit opening wherein the nozzle has a ratio of channel length to exit opening diameter of less than 7; and
a power source for forcing formulation through the channel and out of the exit opening at a rate of 500 microliters or more per second.
18. The injector of claim 17 , wherein and the power source forces the formulation out of the exit opening at a rate of 5,000 microliters or more per second.
19. The injector of claim 17 , wherein the viscosity of the liquid is more than 10 cS at 20° C.
20. The injector of claim 19 , wherein the formulation is a viscous controlled release formulation.
21. The injector of claim 17 , wherein the viscosity of the liquid is 20 cS or more at 20° C. and the ratio of channel length to exit opening diameter is less than 5.
22. The injector of claim 17 , wherein the viscosity of the formulation is 100 cS or more at 20° C.
23. The injector of claim 17 , wherein the ratio of channel length to exit opening diameter is 1.7 ±20%.
24. The injector of claim 17 , wherein the viscosity of the formulation is 1000 cS or more at 20° C.
25. The injector of claim 17 , wherein the drug is a psychiatric drug.
26. The injector of claim 25 , wherein the psychiatric drug is selected from the group consisting of chlorpromazine, fluphenazine, mesoridazine, perphenazine, prochlorperazine, promazine, thioridazine/sulforidazine, trifluoperazine, indoles, butyrophenones, thioxanthenes, diphenylbutylpiperidines, loxapine, butyrophenones, indoles, benzamides, diazepines, oxazepines, thiazepines, aripiprazole, risperidone, paliperidone, zotepine, iloperidone, pharmaceutically acceptable salt and ester forms thereof, and combinations of two or more of these compounds.
27. The injector of claim 25 , wherein the psychiatric drug is selected from the group consisting of molindone, azaperone, benperidol, droperidol, haloperidol, flupentixol, chlorprothixene, thiothixene, zuclopenthixol, fluspirilene, penfluridol, pimozide, loxapine, melperone, sertindole, ziprasidone, sulpiride, remoxipride, amisulpride, clozapine, olanzapine, quetiapine, and pharmaceutically acceptable salts and ester forms, and combinations thereof.
28. The injector of claim 25 , wherein the psychiatric drug comprises risperidone.
29. The injector of claim 28 , wherein the formulation comprises sucrose acetate isobutyrate.
30. A needle-free injector device, comprising:
a container;
a liquid formulation comprised of a pharmaceutically acceptable carrier and pharmaceutically active drug comprising risperidone and sucrose acetate isobutyrate and a viscosity greater than 10 cS at 20° C;
a nozzle leading from the container, the nozzle having channel length and exit opening;
wherein the nozzle has a ratio of channel length to exit opening diameter of less than 7; and
a power source for forcing formulation through the channel and exit opening at a rate of 500 microliters or more per second.
31. The injector of claim 30 , wherein the formulation viscosity is greater than 20 cS at 20° C. and the power source forces the formulation through the channel and exit opening at a rate of 5,000 microliters or more per second and the channel length to exit opening diameter is less than 5.